US Pharma MarketingInfinimmune raises $75m with big pharma backing for atopic dermatitis drugs
Infinimmune raises $75m with big pharma backing for atopic dermatitis drugs is a pharma and life sciences industry update from Pharmaceutical Technology. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
Infinimmune is targeting first-in-human studies with its longer-lasting monoclonal antibodies in 2027.
Source: Pharmaceutical Technology